ArticleInternational microbiology : the official journal of the Spanish Society for Microbiology2025
Genomic characterization of a novel Pseudomonas aeruginosa bacteriophage representing the newly proposed genus Angoravirus: in vitro antimicrobial and antibiofilm activity.
Article in International microbiology : the official journal of the Spanish Society for Microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A novel phage encoding host defense modulators demonstrates in-vivo therapeutic efficacy against carbapenem-resistant E. coli ST1432.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Isolation and Genomic Characterization of LyticLife (Basel, Switzerland) · 2026Article
- Characterization, genomic insights and anti-biofilm potential of phage vB_PaeM_PKMS3, a lytic Pbunavirus capable of infecting clinical Pseudomonas aeruginosa isolates.Antonie van Leeuwenhoek · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Multi-drug-resistant (MDR) Pseudomonas aeruginosa is an important pathogen that poses a critical threat due to its metallo-beta-lactamase (MBL)-mediated carbapenem resistance and biofilm-forming ability, making bacterial treatment very complicated and requiring alternative strategies. Bacteriophages are promising alternatives; however, the discovery of novel phages targeting MDR strains remains urgent. In this study, Pseudomonas phage Baskent_P4_1, a novel virulent siphovirus that infects clinical MDR P. aeruginosa isolates, was isolated from wastewater and characterized comprehensively. Its efficacy was tested against biofilm-forming, MDR isolates with MBL activity by spot test and efficiency of plating (EOP). Biological characterization showed that phage Baskent_P4_1 is stable at pH 4-10 and temperatures up to 50 °C, while its stability decreases >60 °C temperature. It has a short latent period of 10 min and a high burst size of 253 phages per cell. The phage lysed 40% of the MDR P. aeruginosa isolates tested, including strong biofilm producers. In vitro assays showed significant biofilm inhibition (48.8% reduction at 10⁹ PFU/mL) and degradation of pre-formed biofilms. Transmission electron microscopy (TEM) revealed an icosahedral head (70 nm) and a long non-contractile tail (150 nm). Whole genome sequencing by Illumina demonstrated a linear dsDNA genome of 41.947 bp (62.8% GC content) with 53 predicted coding sequences. No virulence factors, antibiotic resistance genes, or tRNAs were detected, thus ensuring therapeutic safety. Along with phylogenetic and vConTACT2 analysis, these results suggested that phage Baskent_P4_1 belongs to a new genus, which was proposed here as the genus Angoravirus with three other species. Genomic analysis identified hydrolases (ORF 13/14) and 7-deazaguanine modification enzymes (ORF 46/47) that may contribute to host lysis and evasion of bacterial defenses. These findings highlight Baskent_P4_1's potential as a therapeutic candidate against MDR P. aeruginosa infections. The study underscores the importance of expanding phage diversity libraries and provides a framework for characterizing novel phages to combat antimicrobial resistance.
Indexed as
Identifiers
40338461What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.